ADMA Biologics shares are trading higher after the company issued a response to short seller Culper Research to refute key allegations and alleviate confusion in the marketplace.

Benzinga Newsdesk www.benzinga.com Positive 93.6%

Neg 0% Neu 0% Pos 93.6%

Comments

No comments yet. Be the first!